Skip to main content
. 2018 Mar 8;4:150–160. doi: 10.1016/j.trci.2018.02.002

Table 3.

Schedule of assessments (abridged)

Time point Screening Baseline (W1) Q2 weeks after BL W4 Q12 weeks after BL up to W52 W16 W26 W38 W52 Q26 weeks after W52 W104 W260 W274
Medical history X
Physical and neurological examination X X X X X X X X X X
Criteria for MCI/AD X X X X X X
GDS X X X X X X
Subjective memory checklist X X X X X X
Screening cognitive battery X
Composite cognitive battery X X X X X X X X
Extended cognitive battery X X X X X X
CDR X X X X X X
FAST X X X X X X
NPI X X X X X X
Suicidality assessment X X X X X X X X
Safety laboratories X X X X X X X X X X X
DNA (APOE, PSEN1); optional DNA for repository X
ECG X X X X X X X X X
PK, PD, and exploratory serum, plasma, RNA samples X X X X X X X X X X X
ATA sample X X X X X X X
Urine screen for drugs of abuse X X X X
Serum pregnancy test X
Vital signs X X X X X X X X X X X X X
Dispense study medication X X X X X X X X X X
Concomitant medication X X X X X X X X X X X X X
Interval medical history and adverse events X X X X X X X X X X X X
Urine pregnancy test X X X X X X X X X X X X
Brain MRI X X X X X X X X
Lumbar puncture for CSF samples (optional) X X X
Fibrillar amyloid PET imaging X X X
FDG PET X X X X X

Abbreviations: AD, Alzheimer's disease; APOE, apolipoprotein; ATA, antitherapeutic antibody; CDR, Clinical Dementia Rating Scale; CSF, cerebrospinal fluid; DNA, deoxyribonucleic acid; ECG, electrocardiogram; FAST, Functional Assessment Staging Test; FDG, fluorodeoxyglucose; GDS, Geriatric Depression Scale; MCI, mild cognitive impairment; MRI, magnetic resonance imaging; NPI, Neuropsychiatric Inventory; PD, pharmacodynamic; PET, positron emission tomography; PK, pharmacokinetic; PSEN1, presenilin 1; RNA, ribonucleic acid.